These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
833 related articles for article (PubMed ID: 35412531)
21. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727 [TBL] [Abstract][Full Text] [Related]
22. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336 [TBL] [Abstract][Full Text] [Related]
23. Clinical Acquired Resistance to KRAS Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136 [TBL] [Abstract][Full Text] [Related]
24. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L; Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316 [TBL] [Abstract][Full Text] [Related]
25. The KRAS-G12C inhibitor: activity and resistance. Liu J; Kang R; Tang D Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232 [TBL] [Abstract][Full Text] [Related]
26. Sotorasib for Lung Cancers with Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690 [TBL] [Abstract][Full Text] [Related]
27. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Bungaro M; Novello S; Passiglia F Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791 [TBL] [Abstract][Full Text] [Related]
29. Nonclinical Safety Profile of Sotorasib, a KRAS Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282 [TBL] [Abstract][Full Text] [Related]
30. Sotorasib for previously treated colorectal cancers with KRAS Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824 [TBL] [Abstract][Full Text] [Related]
31. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. Manabe T; Bivona TG J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243 [TBL] [Abstract][Full Text] [Related]
32. Acquired Resistance to KRAS Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704 [TBL] [Abstract][Full Text] [Related]
33. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report. Iska S; Alley EW Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835 [TBL] [Abstract][Full Text] [Related]
34. HER2 mediates clinical resistance to the KRAS Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459 [TBL] [Abstract][Full Text] [Related]
35. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. Naim N; Moukheiber S; Daou S; Kourie HR Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654 [TBL] [Abstract][Full Text] [Related]
37. First-in-Humans PET Imaging of Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842 [TBL] [Abstract][Full Text] [Related]
38. KRAS-targeted therapy in the treatment of non-small cell lung cancer. Yun J; Nakagawa R; Tham K J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195 [TBL] [Abstract][Full Text] [Related]